170856-15-2

Upstream product

• 621-29-4 3-tolyl isocyanate 
• 170856-32-3 3-amino-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione 
• 170856-14-1 1,5-dihydrobenzo[b][1,4]diazepine-2,3,4-trione 3-(O-methyloxime) 
• 95-54-5 1,2-diamino-benzene 

Downstream Products

• 170855-43-3 1,5-Bis-(2-triphenylmethyltetrazol-5-ylmethyl)-3-(N'-(m-tolyl)ureido)-1H-1,5-benzodiazepine-2,4(3H,5H)-dione 
• 170855-49-9 1,5-Bis-(m-BOC-aminophenylmethyl)-3-(N'-(m-tolyl)ureido)-1H-1,5-benzodiazepine-2,4(3H,5H)-dione 
• 195622-54-9 1,5-bis-(2-hydroxyethyl)-3-[N'-(m-tolyl)ureido]-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione 

Relevant academic research and scientific papers

Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry

A series of CCK-B/gastrin receptor antagonists, 2,4-dioxo-1,5-benzodiazepine derivatives with a plane of symmetry, were designed, synthesized, and evaluated for antagonistic activity. Structure-activity relationship studies revealed that carbonylmethyl groups at both N-1 and N-5 positions and hydrophilic groups, such as the carboxyl group on the benzene ring attached to the ureido group at the C-3 position, brought about potent affinity and subtype selectivity for CCK-B/gastrin receptors. Several compounds showed excellent in vivo inhibition of gastric acid secretion induced by pentagastrin in anesthetized rats.